May 24, 2019 / 4:43 PM / a month ago

BRIEF-Avexis Receives FDA Approval For Zolgensma, First And Only Gene Therapy For Pediatric Patients With Spinal Muscular Atrophy

May 24 (Reuters) - Novartis AG:

* AVEXIS RECEIVES FDA APPROVAL FOR ZOLGENSMA®, THE FIRST AND ONLY GENE THERAPY FOR PEDIATRIC PATIENTS WITH SPINAL MUSCULAR ATROPHY (SMA)

* AVEXIS - ZOLGENSMA WILL BE MADE AVAILABLE IN THE U.S. AND WILL BE MARKETED BY AVEXIS, A NOVARTIS COMPANY

* AVEXIS - ZOLGENSMA HAS PRIME (PRIORITY MEDICINES) DESIGNATION IN EUROPE, AND IS BEING REVIEWED UNDER ACCELERATED ASSESSMENT PROCEDURE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below